Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models.
作者信息
Charest Alain
机构信息
Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Neuro Oncol. 2022 Mar 12;24(3):396-397. doi: 10.1093/neuonc/noab278.
Abstract
摘要
相似文献
1
Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models.在患者来源的异种移植临床前模型中，优化新型微管靶向药物利沙万布林与胶质母细胞瘤标准治疗方案的有效组合。
Neuro Oncol. 2022 Mar 12;24(3):396-397. doi: 10.1093/neuonc/noab278.
2
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.在胶质母细胞瘤患者来源异种移植（GBM PDX）异种移植中进行临床前模型构建，以指导新型肿瘤检查点控制器利沙万布林（靶向微管）的临床开发。
Neuro Oncol. 2022 Mar 12;24(3):384-395. doi: 10.1093/neuonc/noab162.
3
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).用抗 CD40 和有丝分裂纺锤体检验点控制器 BAL101553（利斯伐他汀）治疗 ICB 耐药性神经胶质瘤。
JCI Insight. 2021 Sep 22;6(18):e142980. doi: 10.1172/jci.insight.142980.
4
Defining the standard of care for high-grade glioma--a NICE deal for patients.界定高级别胶质瘤的护理标准——对患者来说是件好事。
Clin Oncol (R Coll Radiol). 2008 Feb;20(1):97-8. doi: 10.1016/j.clon.2007.09.011. Epub 2007 Oct 24.
5
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.替莫唑胺和其他潜在的用于治疗多形性胶质母细胞瘤的药物。
Neurosurg Clin N Am. 2012 Apr;23(2):307-22, ix. doi: 10.1016/j.nec.2012.01.007.
6
Chemotherapy for glioblastoma multiforme (GBM).多形性胶质母细胞瘤（GBM）的化疗
Surg Neurol. 2006 Feb;65(2):107-8. doi: 10.1016/j.surneu.2005.11.054.
7
Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma.标准剂量替莫唑胺治疗新诊断的胶质母细胞瘤后的弥漫性大 B 细胞淋巴瘤。
Neurology. 2013 Jul 2;81(1):93-4. doi: 10.1212/WNL.0b013e318297eea6. Epub 2013 May 17.
8
Sex as a biological variable in response to temozolomide.性别作为对替莫唑胺反应的生物学变量。
Neuro Oncol. 2017 Jun 1;19(6):873-874. doi: 10.1093/neuonc/nox040.
9
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.首个类烷基化去乙酰化酶抑制剂分子替莫唑胺在胶质母细胞瘤的临床前模型中表现出抗肿瘤作用，并与放射治疗具有协同作用。
J Hematol Oncol. 2018 Feb 27;11(1):32. doi: 10.1186/s13045-018-0576-6.
10
Radiation as a foundation for glioblastoma therapy in elderly patients. In Regard to Arvold et al.放射治疗作为老年胶质母细胞瘤患者治疗的基础。关于阿诺德等人的研究。
Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):217-8. doi: 10.1016/j.ijrobp.2015.05.006.
引用本文的文献
1
Updates in IDH-Wildtype Glioblastoma.IDH 野生型胶质母细胞瘤的最新进展。
Neurotherapeutics. 2022 Oct;19(6):1705-1723. doi: 10.1007/s13311-022-01251-6. Epub 2022 May 31.
本文引用的文献
1
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.在胶质母细胞瘤患者来源异种移植（GBM PDX）异种移植中进行临床前模型构建，以指导新型肿瘤检查点控制器利沙万布林（靶向微管）的临床开发。
Neuro Oncol. 2022 Mar 12;24(3):384-395. doi: 10.1093/neuonc/noab162.
2
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.BAL101553（一种新型纺锤体组装检查点控制器）静脉注射治疗晚期实体瘤的 1/2a 期临床试验。
Br J Cancer. 2020 Oct;123(9):1360-1369. doi: 10.1038/s41416-020-1010-8. Epub 2020 Aug 3.
3
Microtubule-targeting agents and their impact on cancer treatment.微管靶向药物及其对癌症治疗的影响。
Eur J Cell Biol. 2020 May;99(4):151075. doi: 10.1016/j.ejcb.2020.151075. Epub 2020 May 1.
4
EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis.口服微管蛋白结合剂BAL101553使移植胶质母细胞瘤的小鼠长期存活，这与EB1相关，且与肿瘤血管生成的抑制有关。
Oncotarget. 2020 Feb 25;11(8):759-774. doi: 10.18632/oncotarget.27374.
5
Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.广泛的患者来源异种移植瘤的基因组和表型特征反映了胶质母细胞瘤的多样性。
Clin Cancer Res. 2020 Mar 1;26(5):1094-1104. doi: 10.1158/1078-0432.CCR-19-0909. Epub 2019 Dec 18.
6
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors.一项针对 BAL101553 的 1 期研究，这是一种新型的针对微管的肿瘤检查点控制器，以 48 小时输注的方式在晚期实体瘤成人患者中给药。
Invest New Drugs. 2020 Aug;38(4):1067-1076. doi: 10.1007/s10637-019-00850-z. Epub 2019 Aug 30.
7
The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.新型微管靶向剂BAL101553与放射疗法联合用于难治性肿瘤模型的治疗
Radiother Oncol. 2017 Sep;124(3):433-438. doi: 10.1016/j.radonc.2017.07.024. Epub 2017 Aug 7.
8
The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.新型微管蛋白结合检查点激活剂BAL101553抑制依赖EB1的迁移和侵袭并促进胶质母细胞瘤干细胞样细胞的分化。
Mol Cancer Ther. 2016 Nov;15(11):2740-2749. doi: 10.1158/1535-7163.MCT-16-0252. Epub 2016 Aug 18.
9
A co-clinical platform to accelerate cancer treatment optimization.一个加速癌症治疗优化的联合临床平台。
Trends Mol Med. 2015 Jan;21(1):1-5. doi: 10.1016/j.molmed.2014.10.008. Epub 2014 Nov 17.
10
The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.新型微管去稳定药物 BAL27862 以独特的方式与微管蛋白的秋水仙碱结合部位结合，对微管组织产生影响。
J Mol Biol. 2014 Apr 17;426(8):1848-60. doi: 10.1016/j.jmb.2014.02.005. Epub 2014 Feb 11.
Zotero 插件